Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INMT | O95050 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.30 |
| ▸ | HPGD | P15428 | 3/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824179 | 0.97 | USP2 (0.44) | INMTUSP2ALDH1A1HPGDRAB9A | |
| SCHEMBL17317854 | 0.97 | — | — | |
| SCHEMBL6600866 | 0.97 | USP2 (0.44) | INMTUSP2ALDH1A1HPGDRAB9A | |
| SCHEMBL1828720 | 0.97 | USP2 (0.44) | INMTUSP2ALDH1A1HPGDRAB9A | |
| SCHEMBL206437 | 0.97 | USP2 (0.44) | INMTUSP2ALDH1A1HPGDRAB9A | |
| SCHEMBL204533 | 0.97 | USP2 (0.44) | INMTUSP2ALDH1A1HPGDRAB9A | |
| SCHEMBL19856449 | 0.93 | — | — | |
| SCHEMBL22720891 | 0.93 | — | — | |
| SCHEMBL25355119 | 0.90 | USP2 (0.39) | INMTUSP2ALDH1A1 | |
| SCHEMBL15390690 | 0.90 | USP2 (0.39) | INMTUSP2ALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117720517-A | AR inhibitor, composition thereof and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-03-19 | — | — | CN | claimed |
| WO-2024012570-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 西藏海思科制药有限公司 | 2024-01-18 | — | — | WO | claimed |
| CN-116640157-A | METTL3 inhibitor and composition thereof and application of METTL3 inhibitor and composition thereof in medicine | 海思科医药集团股份有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-114805199-A | Benzene ring derivative and application thereof in medicine | 海思科医药集团股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| EP-3057422-A1 | QUINOLINYL MODULATORS OF ROR(GAMMA)T | Janssen Pharmaceutica NV (BE) | 2016-08-24 | — | — | EP | claimed |
| WO-2015057626-A1 | QUINOLINYL MODULATORS OF RORyT | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-23 | — | — | WO | claimed |
| CN-117720517-A | AR inhibitor, composition thereof and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2024012570-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 西藏海思科制药有限公司 | 2024-01-18 | — | — | WO | disclosed |
| WO-2023208165-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2023-11-02 | — | — | WO | disclosed |
| CN-116640157-A | METTL3 inhibitor and composition thereof and application of METTL3 inhibitor and composition thereof in medicine | 海思科医药集团股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2011-07-28 | — | — | US | disclosed |
| EP-2318400-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010013037-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-02-04 | — | — | WO | disclosed |
| US-5965745-A | ASTHMA; ANTIARTHRITIC,-SHOCK AGENTS; BRONCHITIS; RESPIRATORY SYSTEM DISEASES, E.G. CHRONIC OBSTRUCTIVE AIRWAYS DISEASES; PSORIASIS; ALLERGIC RHINITIS; ATOPIC DERMATITIS | PFIZER INC (US) | 1999-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183974-A1 | 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | SHH, SMO, GLI1 | INMT 2660/4885USP2 1242/4885CHKA 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.